Epoxyeicosatrienoic acids (EETs) are lipid metabolites that regulate blood pressure and inflammation. EETs are metabolized by soluble epoxide hydrolase (sEH); therefore, inhibition of sEH may treat hypertension and other medical conditions caused by irregularities in blood pressure, vasodilation, endothelial cell function, and inflammation. However, treatments for these conditions, based on this strategy, do not currently exist because the best-known inhibitors of sEH have poor bioavailability. This technology is a class of potent sEH inhibitors with improved biocompatibility. These inhibitors may potentially be used to treat hypertension, metabolic syndrome, atherosclerosis, erectile dysfunction, stroke, diabetes, and aging in humans. Additionally, these inhibitors may be used to treat laminitis disease in horses.
The most potent sEH inhibitors are urea-based and are readily metabolized in vivo, limiting their use as pharmaceuticals. The inhibitors described by this technology are based on a stronger and less metabolically active chemical functionality, and are thus more attractive drug candidates. These small molecules are potent inhibitors of sEH in low nanomolar concentrations (IC50's < 2 nM).
Studies investigating the pharmacokinetic profile of these molecules are currently underway.
Tech Ventures Reference: IR 2436
Pecic S, Pakhomova S, Newcomer ME, Morisseau C, Hammock BD, Zhu Z, Rinderspacher A, Deng SX. "Synthesis and structure-activity relationship of piperidine-derived non-urea soluble epoxide hydrolase inhibitors." Bioorg Med Chem Lett. 2013 Jan 15;23(2):417-21.
Pecic S, Deng SX, Morisseau C, Hammock BD, Landry DW. "Design, synthesis and evaluation of non-urea inhibitors of soluble epoxide hydrolase." Bioorg Med Chem Lett. 2012 Jan 1;22(1):601-5.
Xie Y, Liu Y, Gong G, Smith DH, Yan F, Rinderspacher A, Feng Y, Zhu Z, Li X, Deng SX, Branden L, Vidovic D, Chung C, Schuerer S, Morisseau C, Hammock BD, Landry DW. "Discovery of potent non-urea inhibitors of soluble epoxide hydrolase." Bioorg Med Chem Lett. 2009 Apr 15;19(8):2354-9.
由于技术保密工作限制,技术信息无法完全展现,请通过邮箱或短信联系我们,获取更多技术资料。
summary epoxyeicosatrienoic acids
soluble epoxide hydrolase
endothelial cell function
attractive drug candidates
low nanomolar concentrations
